HER2-inhibitors, such as lapatinib and afatinib, are mostly associated with heart failure with left ventricular dysfunction and systemic hypertension.725 VEGFR (and PDGFR) inhibitors may cause systemic hypertension, the highest incidence being reported with lenvatinib but also observed with cabozantinib, vandetanib and regorafenib; QTc prolongation (axitinib, regorafenib), pulmonary hypertension (lapatinib, lorlatinib) and arterial thrombosis added to the heart failure or systemic hypertension that is associated to all VEGFR inhibitors. The gene discussed is KDR; the disease is pulmonary hypertension.